Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.
Study Finds on MSN
Injectable filler made from donated skin shows promise for breast reconstruction in cancer patients
In A Nutshell Korean researchers developed SC Fill paste, an injectable tissue filler made from processed human skin that ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation ...
Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.
Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the ...
NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...
With the holidays wrapping up, South Carolina doctors say they are expecting a spike in heart failure caused by stress as the ...
Complications from an epidural injection led to a wrongful death suit against MUSC in Charleston and ultimately a payout by ...
Since executions resumed in Sept. 2024, seven men have been executed by lethal injection and firing squad in South Carolina.
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback